Latest Headlines

Latest Headlines

In $171M deal, Bavarian Nordic and J&J;'s Janssen extend efforts to HPV

Building on a relationship struck last fall, Bavarian Nordic and Johnson & Johnson's Janssen unit inked a deal on Friday potentially worth $171 million plus milestones aimed at the development of a therapeutic HPV vaccine.

UPDATED: J&J; slapped with $1.75M verdict in Risperdal breast growth case

Johnson & Johnson lost another courtroom battle over claims that the company failed to warn doctors and patients that its antipsychotic drug Risperdal could cause breast growth in boys, a blow for the company as it continues to deal with related cases.

Injectable HIV regimen being developed by J&J; and ViiV Healthcare shows promise in trials

Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.

Janssen the latest Big Pharma to join Hanmi's South Korea deal machine

South Korea's Hanmi Pharmaceutical has licensed long-acting GLP/GCG analog diabetes and obesity candidate HM12525A to Janssen Pharmaceuticals, showcasing a deal making spree this year with major drug firms that includes two blockbusters this month alone.

J&J;'s Yondelis finally captures FDA nod, but path to big sales could be steep

Once upon a time, analysts thought the cancer-fighting prospect Yondelis could hit $1 billion in sales by 2010. But that timetable went poof years ago--and so did the forecast--as the drug failed to win the FDA's approval, and eventually ended up in a partnership between Spain's Zeltia and Johnson & Johnson's Janssen unit.

J&J; brings Ebola vaccine to trial in Sierra Leone

Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.

HIV activists join Janssen's story-focused Prezcobix effort

Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease.

Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest

Some heavy-hitting HIV activists have signed onto Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease. The Johnson & Johnson unit will award up to $20,000 in charitable donations as part of the effort, which ties in the company's latest HIV brand, Prezcobix.

J&J;'s Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine

Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.

Janssen's new Prezcobix push urges HIV patients to share pics with their docs

Say cheese, bus shelter ad. Janssen's Prezcobix campaign advocates a new way for potential patients to talk to their doctors: Snap a picture and share it.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • next ›
  • last »